Dataset opportunity
Eumediq — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Eumediq, usable for Diagnostic AI and Computer Vision.
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market = $1.75B in 2024, CAGR 30% (source: rootsanalysis.com) [7]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-24
FDA drops Whoop warning letter over blood pressure feature
medtechdive.com ↗ - 📰press2026-06-24
FedEx launches life sciences suite as healthcare push lifts earnings
supplychaindive.com ↗ - 📰press2026-06-24
MiniMed launches Abbott-made Instinct glucose sensor in Europe
medtechdive.com ↗ - 📰press2026-06-24
J&J commits $1B to expand contact lens production in Florida
supplychaindive.com ↗ - 📰press2026-06-23
Medtronic appoints veteran J&J exec as first CFO of innovation
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Eumediq holds a proprietary Medical Imaging Dataset derived from clinical activities related to its medical devices. This collection is enriched with corresponding medical records and regulatory documentation, providing a comprehensive and authentic source of data ideal for training, testing, and validating Diagnostic AI models. The dataset's structure is optimized for developing algorithms that require high-quality, contextualized evidence.
This data is positioned in the rapidly growing AI in Medical Imaging market, which was valued at $1.75 billion in 2024 and is projected to expand at a 30% CAGR. [7] While access is subject to strict GDPR and MDR compliance and requires robust anonymization protocols, the rarity and depth of this clinical data offer a significant competitive advantage. It represents a crucial asset for AI developers seeking to create highly accurate and compliant diagnostic solutions in a market with immense growth potential. ⚠ Diligence (valuable data, access to negotiate): Highly sensitive medical device clinical data; Data subject to strict GDPR and MDR (Medical Device Regulation) compliance; Access likely requires anonymization protocols · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Eumediq possesses a proprietary dataset of medical images, systematically gathered and analyzed for clinical evaluation reports under European medical device regulations. This structured data, complete with post-market surveillance and risk management documentation, is a rare asset for medical AI firms developing diagnostic imaging algorithms. In a global AI medical imaging market projected to grow at 30% annually from its current $1.75 billion valuation, this dataset offers a critical advantage for model validation and regulatory approval.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
AI buyer demand is exceptionally high, driven by the AI in Medical Imaging market's rapid expansion at a 30% CAGR, creating an urgent need for high-quality, compliant clinical data. [7]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ review — Eumediq is a regulatory consulting firm and SaaS provider whose core business is selling services and intelligence to the MedTech industry, making it a bad target as it does not hold proprietary operational data. Issues: Company's core business is selling services and intelligence (consulting, AI software), which is an explicit exclusion criterion. [2, 5, 12]; Does not own proprietary data generated as a by-product of a non-data business; it is a pure service/SaaS vendor. [5, 6]; The
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence indicates the dataset contains medical images that have undergone formal clinical data analysis for European regulatory submissions, providing essential context for AI model training and validation.
Regulatory records
This demonstrates an established process for post-market surveillance, providing a continuous stream of real-world performance data essential for ongoing AI model monitoring and satisfying regulatory obligations.
Industrial data
This points to the existence of structured technical documentation and risk management files, which establish clear data provenance and are critical for de-risking the development of commercial diagnostic AI tools.
Coverage
Scanned sources
Deliverable
Premium dataset report
Eumediq Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.75B in 2024, CAGR 30% (source: rootsanalysis.com) [7]. Investment score 45.0/100 (confidence 0.49). Recommended action: Data Sharing Agreement.